Reply

Mark Parsons(University of Newcastle Australia), Christopher Levi(John Hunter Hospital), Elizabeth Pepper(John Hunter Hospital), Siva Rajaratnam(John Hunter Hospital), Virgil Chan(John Hunter Hospital), Grant A. Bateman(John Hunter Hospital), Siva Rajarabram(John Hunter Hospital), Sabbir Siddique(John Hunter Hospital)
Annals of Neurology
March 24, 2006
10.1002/ana.20839
Cited by 4

Related Papers

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials
|The Lancet|2014|2.7k
Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke
|New England Journal of Medicine|2016|437
Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial
|The Lancet|2019|271
Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4·5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial
|The Lancet|2022|225
Perfusion computed tomography: Prediction of final infarct extent and stroke outcome
|Annals of Neurology|2005|207